首页 | 本学科首页   官方微博 | 高级检索  
     

曲伏前列素滴眼液抗青光眼治疗中对眼表影响的观察
引用本文:谭业双,周霞,樊玲,王娜娜,何娟. 曲伏前列素滴眼液抗青光眼治疗中对眼表影响的观察[J]. 国际眼科杂志, 2014, 14(6): 1107-1109
作者姓名:谭业双  周霞  樊玲  王娜娜  何娟
作者单位:中国湖北省十堰市,湖北医药学院附属太和医院眼科;中国湖北省十堰市,湖北医药学院附属太和医院眼科;中国湖北省十堰市,湖北医药学院附属太和医院眼科;中国湖北省十堰市,湖北医药学院附属太和医院眼科;中国湖北省十堰市,湖北医药学院附属太和医院眼科
摘    要:目的:探讨局部应用抗青光眼药物曲伏前列素滴眼液对患者泪膜功能的影响。方法:选取原发性开角型青光眼或高眼压患者18例32眼。患者均局部用曲伏前列素滴眼液,每晚滴1次。用药前及用药后1,2,3mo行症状评分及基础泪液分泌量测定(Schirmer Ⅰ test ,SⅠt)、角膜荧光素染色(corneal fluorescein staining,FL)、泪膜破裂时间(tear break-up time, BUT)。结果:全部患者用药前患者症状评分、FL的平均值为1.34±1.56,0.44±0.73,用药后1,2,3mo分别为2.75±1.63,1.08±0.84; 5.10±1.68,1.53±0.67; 6.33±1.40,1.98±0.50。用药后1,2,3mo患者症状评分、FL均显著高于用药前(P=0.00),且逐渐增加。全部患者用药前患者症状BUT,SⅠt的平均值为(7.76±0.92s),(8.47±2.73mm/5min),用药后1,2,3mo分别(7.08±1.15s),(7.73±3.44mm/5min);(5.59±1.33s),(6.82±3.05mm/5min);(4.29±1.87s),(6.04±3.15mm/5min)。用药后1,2,3mo患者BUT 值和SⅠt值均显著低于用药前水平(P=0.00),且逐渐减低。结论:短期使用曲伏前列素滴眼液即加重患者角膜刺激症状,泪膜稳定性下降, 泪液分泌减少。

关 键 词:青光眼  高眼压症  曲伏前列素滴眼液  泪膜功能
收稿时间:2014-02-20
修稿时间:2014-05-07

Clinical study of adverse effects induced by Travoprost eyedrops on ocular surface
Ye-Shuang Tan,Xia Zhou,Ling Fan,Na-Na Wang and Juan He. Clinical study of adverse effects induced by Travoprost eyedrops on ocular surface[J]. International Eye Science, 2014, 14(6): 1107-1109
Authors:Ye-Shuang Tan  Xia Zhou  Ling Fan  Na-Na Wang  Juan He
Affiliation:Department of Ophthalmology, Taihe Hospital Affiliated to Hubei University of Medicine, Shiyan 442000, Hubei Province, China;Department of Ophthalmology, Taihe Hospital Affiliated to Hubei University of Medicine, Shiyan 442000, Hubei Province, China;Department of Ophthalmology, Taihe Hospital Affiliated to Hubei University of Medicine, Shiyan 442000, Hubei Province, China;Department of Ophthalmology, Taihe Hospital Affiliated to Hubei University of Medicine, Shiyan 442000, Hubei Province, China;Department of Ophthalmology, Taihe Hospital Affiliated to Hubei University of Medicine, Shiyan 442000, Hubei Province, China
Abstract:AIM: To evaluate the effects induced by topical antiglaucomatous drugs, Travoprost eyedrops on tear film. METHODS: Eighteen patients(32 eyes)with primary open-angle glaucoma or ocular hypertension were all treated with Travoprost eyedrops once every night. The symptom score, Schirmer's test(SⅠt), corneal fluorescein staining(FL), tear film break-up time(BUT), were observed before the treatment and 1, 2 and 3mo after the treatment. RESULTS: The average symptom score, FL of all patients were 1.34±1.56 and 0.44±0.73 before the treatment, and 2.75±1.63, 1.08±0.84; 5.10±1.68, 1.53±0.67; 6.33±1.40, 1.98±0.50 respectively after 1, 2 and 3mo of the treatment. There was significant increase in symptom score and FL after the treatment for 1, 2 and 3mo(P=0.00). The average BUT, SⅠt of all patients were(7.76±0.92s),(8.47±2.73mm/5min)before the treatment, and(7.08±1.15s),(7.73±3.44mm/5min);(5.59±1.33s),(6.82±3.05mm/5min);(4.29±1.87s),(6.04±3.15mm/5min)respectively after 1, 2 and 3mo of the treatment. There was significant decrease in BUT and ST after the treatment for 1, 2 and 3mo(P=0.00).CONCLUSION: Travoprost eyedrops can obviously aggravate patients' corneal irritation after treatment. Our results show abnormal decreased tear secretion and stability of tear film induced by Travoprost eyedrops over the short term.
Keywords:glaucoma   ocular hypertension   Travoprost eyedrops   tear film function
本文献已被 CNKI 维普 等数据库收录!
点击此处可从《国际眼科杂志》浏览原始摘要信息
点击此处可从《国际眼科杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号